{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:51:48Z","timestamp":1785192708963,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00393-022-01281-7","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T19:04:33Z","timestamp":1667934273000},"page":"829-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nierenbeteiligung bei Kollagenosen","Renal manifestations in connective tissue diseases"],"prefix":"10.1007","volume":"81","author":[{"given":"Georg R.","family":"Herrnstadt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver M.","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Melderis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"1281_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1191\/0961203302lu158oa","volume":"11","author":"HM Bastian","year":"2002","unstructured":"Bastian\u00a0HM, Roseman\u00a0JM, McGwin\u00a0G et\u00a0al (2002) Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11:152\u2013160","journal-title":"Lupus"},{"key":"1281_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00393-018-0496-4","volume":"77","author":"S Melderis","year":"2018","unstructured":"Melderis\u00a0S, Wiech\u00a0T, Iking-Konert\u00a0C, Steinmetz\u00a0OM (2018) Lupus nephritis. Z\u00a0Rheumatol 77:593\u2013608","journal-title":"Z Rheumatol"},{"key":"1281_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2015","unstructured":"Hanly\u00a0JG, O\u2019Keeffe\u00a0AG, Su\u00a0L et\u00a0al (2015) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55:252\u2013262","journal-title":"Rheumatology (Oxford)"},{"key":"1281_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani\u00a0S, Meara\u00a0A, Rovin\u00a0BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12:825\u2013835","journal-title":"Clin J Am Soc Nephrol"},{"key":"1281_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/ard.62.6.556","volume":"62","author":"P Alba","year":"2003","unstructured":"Alba\u00a0P, Bento\u00a0L, Cuadrado\u00a0MJ et al (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 62:556\u2013560","journal-title":"Ann Rheum Dis"},{"key":"1281_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","volume":"90","author":"HJ Anders","year":"2016","unstructured":"Anders\u00a0HJ, Rovin\u00a0B (2016) A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 90:493\u2013501","journal-title":"Kidney Int"},{"key":"1281_CR7","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2215\/CJN.14721219","volume":"15","author":"JM Halimi","year":"2020","unstructured":"Halimi\u00a0JM, Gatault\u00a0P, Longuet\u00a0H et\u00a0al (2020) Major bleeding and risk of death after percutaneous native kidney biopsies a\u00a0french nationwide cohort study. Clin J Am Soc Nephrol 15:1587\u20131594","journal-title":"Clin J Am Soc Nephrol"},{"key":"1281_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema\u00a0IM, Wilhelmus\u00a0S, Alpers\u00a0CE et\u00a0al (2018) Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int 93:789\u2013796","journal-title":"Kidney Int"},{"key":"1281_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou\u00a0MG, Dasgupta\u00a0A, Ward\u00a0MM (2016) Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68:1432\u20131441","journal-title":"Arthritis Rheumatol"},{"key":"1281_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5606\/ArchRheumatol.2017.6127","volume":"33","author":"H Wang","year":"2018","unstructured":"Wang\u00a0H, Ren\u00a0Y, Chang\u00a0J et al (2018) A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol 33:17\u201325","journal-title":"Arch Rheumatol"},{"key":"1281_CR11","doi-asserted-by":"publisher","first-page":"S713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Cheema\u00a0K et al (2020) 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:S713\u2013S723","journal-title":"Ann Rheum Dis"},{"key":"1281_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Adler\u00a0SG, Barratt\u00a0J et\u00a0al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276","journal-title":"Kidney Int"},{"key":"1281_CR13","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1016\/j.lpm.2014.03.007","volume":"43","author":"N Costedoat-Chalumeau","year":"2014","unstructured":"Costedoat-Chalumeau\u00a0N, Dunogu\u00e9\u00a0B, Morel\u00a0N et al (2014) Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 43:e167\u201380","journal-title":"Presse Med"},{"key":"1281_CR14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"1281_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel\u00a0GB, Contreras\u00a0G, Dooley\u00a0MA et\u00a0al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J\u00a0Am Soc Nephrol 20:1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"1281_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/lupus-2015-000123","volume":"2","author":"F Tamirou","year":"2015","unstructured":"Tamirou\u00a0F, Lauwerys\u00a0BR, Dall\u2019Era\u00a0M et al (2015) A proteinuria cut-off level of 0.7\u202fg \/day after 12\u00a0months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial. Lupus Sci Med 2:1\u20135","journal-title":"Lupus Sci Med"},{"key":"1281_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N\u00a0Engl J Med 383:1117\u20131128","journal-title":"N Engl J Med"},{"key":"1281_CR18","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Teng\u00a0YKO, Ginzler\u00a0EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070\u20132080","journal-title":"Lancet"},{"key":"1281_CR19","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1681\/ASN.2017030263","volume":"28","author":"H Zhang","year":"2017","unstructured":"Zhang\u00a0H, Liu\u00a0Z, Zhou\u00a0M et\u00a0al (2017) Multitarget therapy for maintenance treatment of lupus nephritis. J\u00a0Am Soc Nephrol 28:3671\u20133678","journal-title":"J Am Soc Nephrol"},{"key":"1281_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin\u00a0BH, Furie\u00a0R, Latinis\u00a0K et\u00a0al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64:1215\u20131226","journal-title":"Arthritis Rheum"},{"key":"1281_CR21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","volume":"72","author":"MB Condon","year":"2013","unstructured":"Condon\u00a0MB, Ashby\u00a0D, Pepper\u00a0RJ et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72:1280\u20131286","journal-title":"Ann Rheum Dis"},{"key":"1281_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin\u00a0BH, Furie\u00a0R, Teng\u00a0YKO et\u00a0al (2022) A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101:403\u2013413","journal-title":"Kidney Int"},{"key":"1281_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie\u00a0RA, Aroca\u00a0G, Cascino\u00a0MD et al (2022) B\u2011cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a\u00a0randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107","journal-title":"Ann Rheum Dis"},{"key":"1281_CR24","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie\u00a0RA, Morand\u00a0EF, Bruce\u00a0IN et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a\u00a0randomised, controlled, phase 3 trial. Lancet Rheumatol 1:e208\u2013e219","journal-title":"Lancet Rheumatol"},{"key":"1281_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N\u00a0Engl J Med 382:211\u2013221","journal-title":"N Engl J Med"},{"key":"1281_CR26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/biomedicines10061409","volume":"10","author":"B Obri\u0219c\u0103","year":"2022","unstructured":"Obri\u0219c\u0103\u00a0B, Vornicu\u00a0A, Procop\u00a0A et al (2022) A histology-guided approach to the management of patients with lupus nephritis: are we there yet? Biomedicines 10:1409","journal-title":"Biomedicines"},{"key":"1281_CR27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/0961203321995251","volume":"30","author":"U Das","year":"2021","unstructured":"Das\u00a0U, Patel\u00a0R, Guditi\u00a0S, Taduri\u00a0G (2021) Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis. Lupus 30:876\u2013883","journal-title":"Lupus"},{"key":"1281_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette\u00a0X, Criswell\u00a0LA (2018) Primary Sj\u00f6gren\u2019s syndrome. N\u00a0Engl J Med 378:931\u2013939","journal-title":"N Engl J Med"},{"key":"1281_CR29","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/ndt\/16.12.2328","volume":"16","author":"N Bossini","year":"2001","unstructured":"Bossini\u00a0N, Savoldi\u00a0S, Franceschini\u00a0F et\u00a0al (2001) Clinical and morphological features of kidney involvement in primary Sj\u00f6gren\u2019s syndrome. Nephrol Dial Transplant 16:2328\u20132336","journal-title":"Nephrol Dial Transplant"},{"key":"1281_CR30","first-page":"3252","volume":"123","author":"DF Lin","year":"2010","unstructured":"Lin\u00a0DF, Yan\u00a0SM, Zhao\u00a0Y et\u00a0al (2010) Clinical and prognostic characteristics of 573\u00a0cases of primary Sj\u00f6gren\u2019s syndrome. Chin Med J (Engl) 123:3252\u20133257","journal-title":"Chin Med J (Engl)"},{"key":"1281_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nrneph.2015.174","volume":"12","author":"H Fran\u00e7ois","year":"2016","unstructured":"Fran\u00e7ois\u00a0H, Mariette\u00a0X (2016) Renal involvement in primary Sj\u00f6gren syndrome. Nat Rev Nephrol 12:82\u201393","journal-title":"Nat Rev Nephrol"},{"key":"1281_CR32","first-page":"kew376","volume":"56","author":"M Jasiek","year":"2016","unstructured":"Jasiek\u00a0M, Karras\u00a0A, Le Guern\u00a0V et al (2016) A multicentre study of 95 biopsy-proven cases of renal disease in primary Sj\u00f6gren\u2019s syndrome. Baillieres Clin Rheumatol 56:kew376","journal-title":"Baillieres Clin Rheumatol"},{"key":"1281_CR33","first-page":"278","volume":"35","author":"H Ren","year":"2008","unstructured":"Ren\u00a0H, Wang\u00a0WM, Chen\u00a0XN et\u00a0al (2008) Renal involvement and followup of 130\u00a0patients with primary Sj\u00f6gren\u2019s syndrome. J\u00a0Rheumatol 35:278\u2013284","journal-title":"J Rheumatol"},{"key":"1281_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12891-015-0858-x","volume":"17","author":"RDR Evans","year":"2016","unstructured":"Evans\u00a0RDR, Laing\u00a0CM, Ciurtin\u00a0C, Walsh\u00a0SB (2016) Tubulointerstitial nephritis in primary Sj\u00f6gren syndrome: clinical manifestations and response to treatment. BMC Musculoskelet Disord 17:2","journal-title":"BMC Musculoskelet Disord"},{"key":"1281_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n\u00a0P, Baldini\u00a0C, Bootsma\u00a0H et al (2016) Sj\u00f6gren syndrome. Nat Rev Dis Primers 2:1\u201320","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1281_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals\u00a0M, Brito-Zer\u00f3n\u00a0P, Bombardieri\u00a0S et al (2020) EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis 79:3\u201318","journal-title":"Ann Rheum Dis"},{"key":"1281_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman\u00a0SJ, Fox\u00a0R, D\u00f6rner\u00a0T et al (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a\u00a0randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399:161\u2013171","journal-title":"Lancet"},{"key":"1281_CR38","first-page":"29","volume":"21","author":"VD Steen","year":"2003","unstructured":"Steen\u00a0VD, Mayes\u00a0MD, Merkel\u00a0PA (2003) Assessment of kidney involvement in SSc. Clin Exp Rheumatol 21:29\u201331","journal-title":"Clin Exp Rheumatol"},{"key":"1281_CR39","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/art.40809","volume":"71","author":"EA Butler","year":"2019","unstructured":"Butler\u00a0EA, Baron\u00a0M, Fogo\u00a0AB et\u00a0al (2019) Generation of a\u00a0core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology. Arthritis Rheumatol 71:964\u2013971","journal-title":"Arthritis Rheumatol"},{"key":"1281_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3899\/jrheum.180582","volume":"47","author":"P Moinzadeh","year":"2020","unstructured":"Moinzadeh\u00a0P, Kuhr\u00a0K, Siegert\u00a0E et\u00a0al (2020) Scleroderma renal crisis: risk factors for an increasingly rare organ complication. J\u00a0Rheumatol 47:241\u2013248","journal-title":"J Rheumatol"},{"key":"1281_CR41","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3899\/jrheum.151353","volume":"43","author":"M Turk","year":"2016","unstructured":"Turk\u00a0M, Pope\u00a0JE (2016) The frequency of scleroderma renal crisis over time: a metaanalysis. J\u00a0Rheumatol 43:1350\u20131355","journal-title":"J Rheumatol"},{"key":"1281_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen\u00a0VD, Medsger\u00a0TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66:940\u2013944","journal-title":"Ann Rheum Dis"},{"key":"1281_CR43","doi-asserted-by":"publisher","first-page":"543704","DOI":"10.1155\/2010\/543704","volume":"2010","author":"I Batal","year":"2010","unstructured":"Batal\u00a0I, Domsic\u00a0RT, Medsger\u00a0TA, Bastacky\u00a0S (2010) Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010:543704","journal-title":"Int J Rheumatol"},{"key":"1281_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s100670050132","volume":"18","author":"H Kobayashi","year":"1999","unstructured":"Kobayashi\u00a0H, Nishimaki\u00a0T, Kaise\u00a0S et al (1999) Immunohistological study endothelin\u20111 and endothelin\u2011A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 18:425\u2013427","journal-title":"Clin Rheumatol"},{"key":"1281_CR45","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","volume":"41","author":"VD Steen","year":"1998","unstructured":"Steen\u00a0VD, Medsger\u00a0TA (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41:1613\u20131619","journal-title":"Arthritis Rheum"},{"key":"1281_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-2141-2","volume":"22","author":"L B\u00fctikofer","year":"2020","unstructured":"B\u00fctikofer\u00a0L, Varisco\u00a0PA, Distler\u00a0O et\u00a0al (2020) ACE inhibitors in SSc patients display a\u00a0risk factor for scleroderma renal crisis\u2014a EUSTAR analysis. Arthritis Res Ther 22:1\u20139","journal-title":"Arthritis Res Ther"},{"key":"1281_CR47","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O, Fransen\u00a0J, Avouac\u00a0J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"1281_CR48","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1159\/000507886","volume":"45","author":"M Chrabaszcz","year":"2020","unstructured":"Chrabaszcz\u00a0M, Ma\u0142yszko\u00a0J, Sikora\u00a0M et\u00a0al (2020) Renal involvement in systemic sclerosis: an update. Kidney Blood Press Res 45:532\u2013548","journal-title":"Kidney Blood Press Res"},{"key":"1281_CR49","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","volume":"43","author":"M Hudson","year":"2014","unstructured":"Hudson\u00a0M, Baron\u00a0M, Tatibouet\u00a0S et al (2014) Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey. Semin Arthritis Rheum 43:666\u2013672","journal-title":"Semin Arthritis Rheum"},{"key":"1281_CR50","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/j.lpm.2014.02.031","volume":"43","author":"VD Steen","year":"2014","unstructured":"Steen\u00a0VD (2014) Kidney involvement in systemic sclerosis. Presse Med 43:e305\u2013e314","journal-title":"Presse Med"},{"key":"1281_CR51","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","volume":"100","author":"H Penn","year":"2007","unstructured":"Penn\u00a0H, Howie\u00a0AJ, Kingdon\u00a0EJ et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100:485\u2013494","journal-title":"QJM"},{"key":"1281_CR52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejim.2021.01.025","volume":"87","author":"G Leodori","year":"2021","unstructured":"Leodori\u00a0G, Pellicano\u00a0C, Gigante\u00a0A, Rosato\u00a0E (2021) Estimated glomerular filtration rate and renal resistive index as possible predictive markers of mortality in systemic sclerosis. Eur J Intern Med 87:83\u201389","journal-title":"Eur J Intern Med"},{"key":"1281_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2022.02.014","author":"A Gigante","year":"2022","unstructured":"Gigante\u00a0A, Leodori\u00a0G, Pellicano\u00a0C et\u00a0al (2022) Assessment of kidney involvement in systemic sclerosis: from scleroderma renal crisis to subclinical renal vasculopathy. Am J Med Sci. https:\/\/doi.org\/10.1016\/j.amjms.2022.02.014","journal-title":"Am J Med Sci"},{"key":"1281_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01181","volume":"9","author":"MG Tektonidou","year":"2018","unstructured":"Tektonidou\u00a0MG (2018) Antiphospholipid syndrome nephropathy: from pathogenesis to treatment. Front Immunol 9:1\u20137","journal-title":"Front Immunol"},{"key":"1281_CR55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1681\/ASN.V13142","volume":"13","author":"E Daugas","year":"2002","unstructured":"Daugas\u00a0E, Nochy\u00a0D, Huong\u00a0DLT et\u00a0al (2002) Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J\u00a0Am Soc Nephrol 13:42\u201352","journal-title":"J Am Soc Nephrol"},{"key":"1281_CR56","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.20433","volume":"50","author":"MG Tektonidou","year":"2004","unstructured":"Tektonidou\u00a0MG, Sotsiou\u00a0F, Nakopoulou\u00a0L et al (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 50:2569\u20132579","journal-title":"Arthritis Rheum"},{"key":"1281_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00393-020-00759-6","volume":"79","author":"C Specker","year":"2020","unstructured":"Specker\u00a0C, Fischer-Betz\u00a0R, D\u00f6rner\u00a0T (2020) Antiphospholipid syndrome: update on diagnostics and management. Z\u00a0Rheumatol 79:255\u2013266","journal-title":"Z Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01281-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T12:06:00Z","timestamp":1670501160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01281-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01281-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"26 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"I.\u00a0K\u00f6tter gibt folgende Interessenkonflikte an: Vortr\u00e4ge: Abbvie, Amgen, Boehringer, EUSA, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, Sobi; Beratung\/Adboards: Amgen, Boehringer, GSK, Novartis, Sobi; Klinische Studien (letzten 5\u00a0Jahre): GSK, Janssen, Lilly, Novartis. G.R.\u00a0Herrnstadt, M.\u2011T.\u00a0Holzer, O.M.\u00a0Steinmetz und S.\u00a0Melderis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}